Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia.

[1]  M. Jacobs,et al.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods , 1997, Antimicrobial agents and chemotherapy.

[2]  D. E. Anderson,et al.  Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model , 1996, Antimicrobial agents and chemotherapy.

[3]  J. Yao,et al.  Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas (Xanthomonas) maltophilia , 1995, Journal of clinical microbiology.

[4]  T. Louie,et al.  Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment , 1995, Journal of clinical microbiology.

[5]  K. Papadakis,et al.  Mucocutaneous and Soft Tissue Infections Caused by Xanthomonas maltophilia: A New Spectrum , 1994, Annals of Internal Medicine.

[6]  M. Kaku,et al.  Pneumonia caused by Stenotrophomonas maltophilia with a mucoid phenotype , 1994, Journal of clinical microbiology.

[7]  M. Jacobs,et al.  Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods , 1994, Antimicrobial Agents and Chemotherapy.

[8]  S. Amyes,et al.  Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia , 1994, Antimicrobial Agents and Chemotherapy.

[9]  G. Bodey,et al.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy , 1994, Antimicrobial Agents and Chemotherapy.

[10]  J. Burke,et al.  Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. , 1992 .

[11]  D. Livermore,et al.  Effect of media composition on the susceptibility of Xanthomonas mahophilia to β-lactam antibiotics , 1991 .

[12]  R. Frei,et al.  In vitro susceptibility of 33 clinical case isolates of Xanthomonas maltophilia. Inconsistent correlation of agar dilution and of disk diffusion test results. , 1991, Diagnostic microbiology and infectious disease.

[13]  M. I. García,et al.  Antibiotic susceptibility profile of Xanthomonas maltophilia in vitro activity of β-lactam/β-lactamase inhibitor combinations , 1991 .

[14]  B. Schable,et al.  Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. , 1990, Reviews of infectious diseases.

[15]  L. Elting,et al.  Septicemia Due to Xanthomonas Species and Non‐Aeruginosa Pseudomonas Species: Increasing Incidence of Catheter‐Related Infections , 1990, Medicine.

[16]  J. Anhalt,et al.  Xanthomonas maltophilia: an emerging nosocomial pathogen. , 1989, Mayo Clinic proceedings.

[17]  H. Neu,et al.  Resistance of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors. , 1989, Diagnostic microbiology and infectious disease.

[18]  A. Chow,et al.  Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia , 1988, Antimicrobial Agents and Chemotherapy.

[19]  V. Yu,et al.  Infections caused by Pseudomonas maltophilia. Expanding clinical spectrum. , 1987, Archives of internal medicine.

[20]  V. Yu,et al.  Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature. , 1982, Reviews of infectious diseases.

[21]  B. Bruun,et al.  Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. , 1994, Scandinavian journal of infectious diseases.

[22]  B. Bruun,et al.  Changing etiology of bacteremia in patients with hematological malignancies in Denmark. , 1994, Scandinavian journal of infectious diseases.

[23]  P. Hawkey,et al.  Effect of divalent cations in bacteriological media on the susceptibility of Xanthomonas maltophilia to imipenem, with special reference to zinc ions. , 1993, The Journal of antimicrobial chemotherapy.

[24]  W. Cullmann.  Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates. , 1991, Chemotherapy.

[25]  G. Kronvall,et al.  Species-specific interpretive breakpoints for ciprofloxacin disk diffusion susceptibility testing. , 1989, Scandinavian journal of infectious diseases. Supplementum.